Abstract
Papillary serous (PS) and clear cell (CC) histologies have been poorly represented or excluded from clinical trials for endometrial cancer. Two large trials (MRC-ASTEC and Italian) recently examined the benefit of pelvic lymph node dissection and adjuvant therapy for early stage disease, though were not powered to detect differences for this subgroup. Our objective is to report predictors of outcome and patterns of recurrence for early stage PS and CC endometrial cancer as well as to analyze extent of nodal dissection on progression free survival (PFS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
